64
Participants
Start Date
June 3, 2021
Primary Completion Date
August 18, 2023
Study Completion Date
August 18, 2023
KPG-818 low dose
The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
KPG-818 mid dose
The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
KPG-818 high dose
The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
Placebo
This is the comparative arm.
Oracle Clinical Research, College Park
Omega Research MetroWest LLC, Orlando
Charisma Medical and Research Center, Miami Lakes
San Marcus Research Clinic, Miami Lakes
OSIS Clinical Research, Hollywood
Hope Clinical Trials, Inc., Coral Gables
SouthCoast Research Center Inc, Miami
D & H National Research Centers, Miami
JY Research Institute Inc, Cutler Bay
Clinical Research of West Florida, Tampa
Clinical Research of West Florida, Inc., Clearwater
University of Alabama - Birmingham, Birmingham
Anniston Medical Clinic, Anniston
Shelby Research LLC, Memphis
STAT Research, Vandalia
Accurate Clinical Management, Houston
Accurate Clinical Research LLC, Houston
Sun Research Institute, San Antonio
Lead Sponsor
Kangpu Biopharmaceuticals, Ltd.
INDUSTRY